Esketamine monotherapy significantly reduced depressive symptoms in adult patients with treatment-resistant depression (TRD) compared to placebo, according to randomized clinical trial results.
Initial data from the core stage of a phase 2b clinical trial showed that an intranasal formulation of mebufotenin benzoate, BPL-003, significantly reduced depressive symptoms in patients with...
The use of ketamine and esketamine as antidepressant treatments may lead to a significantly improved quality of life (QoL) in patients with major depressive disorder (MDD) or treatment-resistant depression...
Adhering to specific dietary patterns, including the Mediterranean diet, may reduce symptoms of depression, according to a recent literature review published in The Australian and New Zealand Journal of...
Following depression screenings, moderate rates of treatment initiation among patients with elevated depressive symptoms and/or suicidal ideation (SI) were found, particularly for those in more-vulnerable...
Esketamine (ESK) nasal spray monotherapy was found to be efficacious over placebo in adults with treatment-resistant depression, according to recent randomized, double-blind study results reported in a...
Rates of clinically diagnosed depression and anxiety without depression increased between 2017 and 2021, especially during the COVID-19 pandemic, according to recent cohort study results published in JAMA...
Chronic pain in youth was associated with an increased risk of anxiety and depression, particularly when compared to symptoms of youth without chronic pain. Results from the systematic review and...
Increases in depressive symptoms during adolescence can persist into young adulthood, according to recent cohort study results published in JAMA Network Open.
